83249-10-9

Usage

Uses

Used in Pharmaceutical Synthesis:
Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, monomethyl ester is used as a reagent for the synthesis of imatinib analogs, which are important in the development of targeted therapies for various cancers.
Used in Biopharmaceutical Evaluation:
Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, monomethyl ester is also used in the biopharmaceutical evaluation of imatinib analogs, helping researchers understand their potential therapeutic effects and safety profiles.
Used in Neuropharmacology Research:
Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, monomethyl ester functions as a reagent for the preparation and biological evaluation of novel bicyclo[1.1.1]pentane-based acidic amino acids, which act as ligands for glutamate receptors. This application is crucial for advancing our understanding of neurological disorders and developing new treatments.
Used in COVID-19 Research:
As a COVID-19-related research product, Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, monomethyl ester may be utilized in the development of antiviral drugs, vaccines, or other therapeutic interventions to combat the virus.

Upstream product

• 311-75-1 bicyclo[1.1.1]pentane 
• 67-56-1 methanol 
• 56842-95-6 bicyclo<1.1.1>pentane-1,3-dicarboxylic acid 
• 5781-53-3 monomethyl oxalyl chloride 
• 35634-10-7 [1.1.1]propellane 
• 110371-22-7 methyl 3-(chlorocarbonyl)bicyclo<1.1.1>pentane-1-carboxylate 
• 83249-04-1 3-phenylbicyclo<1.1.1>pentane-1-carboxylic acid 
• 65862-03-5 methyl 3-phenyl-2,2-dichlorobicyclo<1.1.1>pentanecarboxylate 
• 105542-93-6 1-(1-hydroxyethyl)-3-(1-oxoethyl)bicyclo<1.1.1>pentane 
• 115913-30-9 1,1′-(bicyclo[1.1.1]pentane-1,3-diyl)bis(ethan-1-one) 
• 115913-31-0 1,3-bis(chlorocarbonyl)bicyclo<1.1.1>pentane 
• 115913-32-1 dimethyl bicyclo<1.1.1>pentane-1,3-dicarboxylate 
• 83249-09-6 methyl 3-phenylbicyclo<1.1.1>pentane-1-carboxylate 

Downstream Products

• 131515-46-3 methyl 3-(1,4-benzoquinonyl)bicyclo<1.1.1>pentane-1-carboxylate 
• 83249-09-6 methyl 3-phenylbicyclo<1.1.1>pentane-1-carboxylate 
• 131515-47-4 dimethyl <2>staffane-3,3'-dicarboxylate 
• 262851-99-0 3-fluoro-bicyclo[1.1.1]pentane-1-carboxylic acid methyl ester 
• 83249-22-3 3-[1-Methyl-1-(4-nitro-benzoyloxy)-ethyl]-bicyclo[1.1.1]pentane-1-carboxylic acid methyl ester 
• 1113001-63-0 2-(3-methoxycarbonylbicyclo[1.1.1]pentane)acetic acid 
• 1113001-76-5 3-(tert-butoxycarbonylmethyl)bicyclo[1.1.1]pentane-1-carboxylic acid 
• 1113001-78-7 tert-butyl (3-(hydroxymethyl)bicyclo[1.1.1]pentyl)acetate 
• 1113001-80-1 tert-butyl (3-formylbicyclo[1.1.1]pentane)acetate 
• 1113001-69-6 C₁₈H₂₂N₂O₃ 
• 1113001-71-0 C₁₈H₂₂N₂O₃ 
• 1113001-82-3 C₂₁H₂₈N₂O₃ 
• 1113001-84-5 C₂₁H₂₈N₂O₃ 
• 1370705-39-7 3-(hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile 

Relevant academic research and scientific papers

Large-Scale Synthesis and Modifications of Bicyclo[1.1.1]pentane-1,3-dicarboxylic Acid (BCP)

In flow photochemical addition of propellane to diacetyl allowed construction of the bicyclo[1.1.1]pentane (BCP) core in a 1 kg scale within 1 day. Haloform reaction of the formed diketone in batch afforded bicyclo[1.1.1]pentane-1,3-dicarboxylic acid in a

NLRP3 MODULATORS

The present invention provides compounds of Formula (I): (I) wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

A DNA toxicity dimer compound (by machine translation)

The invention discloses a DNA toxicity dimer compound, with the previous technology disclosed benzo hypnotic benzodiazepines compared with the conjugates, the cytotoxic compound display much higher in vivo therapeutic index (the maximum tolerance dose and the lowest effective dose of ratio). (by machine translation)

Bicyclo[1.1.1]pentane-Derived Building Blocks for Click Chemistry

Syntheses of bicyclo[1.1.1]pentane-derived azides and terminal alkynes – interesting substrates for click reactions – are described. With a few exceptions, these compounds were prepared in two or three steps starting from common synthetic intermediates – the corresponding carboxylic acids. The key step in the synthesis of 1-azidobicyclo[1.1.1]pentanes is a copper-catalysed diazo-transfer reaction with imidazole-1-sulfonyl azide. The preparation of bicyclo[1.1.1]pentyl-substituted alkynes relies on a Seyferth–Gilbert homologation with dimethyl 1-diazo-2-oxopropylphosphonate (Ohira–Bestmann reagent). Both types of target compounds were found to be suitable substrates for click reactions, and thus they are promising building blocks for medicinal, combinatorial and bioconjugate chemistry. A practically important side result of this study was a multigram preparation of Boc-monoprotected 1,3-diaminobicyclo[1.1.1]pentane – a representative bicyclic conformationally restricted diamine derivative.

HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS

Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

METHOD OF PREPARING SUBSTITUTED BICYCLO[1 1 1]PENTANES

The invention relates to a new and efficient process for the preparation of a class of molecules, namely bicyclo[1.1.1]pentanes and derivatives thereof by reaction of [1.1.1]propellane with a variety of reagents under irradiation and/or in the presence of radical initiators to obtain bicyclo[1.1.1]pentanes asymmetrically substituted at position 1 and 3, which are useful as intermediates for the preparation of asymmetrically 1,3-disubstituted bicyclo[1.1.1]pentane derivatives and various physiologically active substances or materials containing these structures.

Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor

Replacement of the central, para-substituted fluorophenyl ring in the γ-secretase inhibitor 1 (BMS-708,163) withthe bicyclo[1.1.1]pentane motif led to the discovery of compound 3, an equipotent enzyme inhibitor with significant improvements in passive permeability and aqueous solubility. The modified biopharmaceutical properties of 3 translated into excellent oral absorption characteristics (～4-fold Cmax and AUC values relative to 1) in a mouse model of γ-secretase inhibition. In addition, SAR studies into other fluorophenyl replacements indicate the intrinsic advantages of the bicyclo[1.1.1]pentane moiety over conventional phenyl ring replacements with respect to achieving an optimal balance of properties (e.g., γ-secretase inhibition, aqueous solubility/permeability, in vitro metabolic stability). Overall, this work enhances the scope of the [1.1.1]-bicycle beyond that of a mere spacer unit and presents a compelling case for its broader application as a phenyl group replacement in scenarios where the aromatic ring count impacts physicochemical parameters and overall drug-likeness.